Edition:
United States

Merck KGaA (MRCG.DE)

MRCG.DE on Xetra

98.18EUR
11:35am EDT
Change (% chg)

€0.16 (+0.16%)
Prev Close
€98.02
Open
€98.52
Day's High
€98.84
Day's Low
€97.27
Volume
340,304
Avg. Vol
515,723
52-wk High
€98.84
52-wk Low
€70.68

MRCG.DE

Chart for MRCG.DE

About

Merck KGaA is a Germany-based company engaged in the pharmaceutical industry. The Company diversifies its activities into four business divisions: Merck Serono; Consumer Health; Merck Millipore, and Performance Materials. Within the Merck Serono division, the Company focuses on therapeutic areas and prescription drugs of... (more)

Overall

Beta: 0.92
Market Cap(Mil.): €12,668.33
Shares Outstanding(Mil.): 129.24
Dividend: 1.05
Yield (%): 1.07

Financials

  MRCG.DE Industry Sector
P/E (TTM): 30.04 36.73 37.52
EPS (TTM): 3.26 -- --
ROI: 5.34 15.28 14.48
ROE: 10.81 16.33 15.65

CORRECTED-BRIEF-Merck KGaA gets EMA acceptance for review of marketing application

* Merck KGaA, Darmstadt, Germany receives European Medicines Agency (EMA) acceptance for review of marketing authorization application for Cladribine tablets Source text for Eikon: Further company coverage: (Bengaluru Newsroom : +1-646-223-8780)

Jul 18 2016

BRIEF-Merck says EMA accepts cladribine for review marketing authorisation application

* EMA has accepted for review marketing authorization application (MAA) of investigational product cladribine tablets for treatment of relapsing-remitting multiple sclerosis Source text for Eikon: Further company coverage:

Jul 18 2016

REFILE-BRIEF-Pfizer and Germany's Merck KGaA initiate phase III trial

* Merck KGaA and Pfizer initiate phase III trial to evaluate avelumab as first-line treatment for ovarian cancer

Jul 07 2016

Pfizer, Germany's Merck begin large ovarian cancer trial

Pfizer Inc and German drugmaker Merck KGaA on Wednesday said they had begun a late-stage trial of their immuno-oncology drug avelumab in combination with standard treatment for ovarian cancer.

Jul 06 2016

BRIEF-Merck KGaA says plans to apply for authorization for Avelumab in H2

* Says plan to apply for marketing authorization for avelumab against merkel cell carcinoma in h2 2016 Further company coverage:

Jun 20 2016

CORRECTED-BRIEF-Merck KGaA, Pfizer present positive mid-stage data on merkel cell carcinoma drug at ASCO

* Say pivotal avelumab study shows positive results in metastatic merkel cell carcinoma

Jun 06 2016

BRIEF-Merck KGaA partners with Array BioPharma, Pierre Fabre on mCRC phase iii trial

* Says partners with Array BioPharma and Pierre Fabre to initiate braf-mutant mCRC phase iii trial Further company coverage:

Jun 04 2016

BRIEF-Merck KGaA expects to file for first approval of Avelumab in H2

* CEO says expects to file for first approval of Avelumab in merkel cell carcinoma in H2 Further company coverage:

May 19 2016

Merck KGaA sees gain in adj EBITDA of up to 18.5 pct

FRANKFURT, May 19 German drugs and chemicals maker Merck KGaA expects adjusted core earnings to increase by up to 18.5 percent this year, helped by additional profit from a takeover of lab supplies maker Sigma-Aldrich.

May 19 2016

Germany's Merck says gene editing to help it outperform

DARMSTADT, Germany Germany's Merck KGaA, the world's second-largest supplier of materials and equipment to the biotech sector, expects to continue delivering market-beating sales growth, helped in part by new gene modification techniques.

May 13 2016

Earnings vs. Estimates